NNV 2
Alternative Names: NNV-2Latest Information Update: 21 May 2024
At a glance
- Originator Calidi Biotherapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses; Stem cell therapies
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Glioblastoma
Most Recent Events
- 14 May 2024 Calidi Biotherapeutics plans a phase I trial for Glioblastoma, in 3Q of 2024
- 02 Aug 2022 US FDA approves IND application for phase I physician-sponsored clinical trial of NNV 2 in Glioma
- 02 Aug 2022 Calidi Biotherapeutics in collaboration with City of Hope plans a phase I physician-sponsored clinical trial for Glioma (Late-stage disease, Recurrent) in USA